Effect of Macrolide Antibiotics on In-Hospital Mortality Among Acute Exacerbation of COPD Patients: A Propensity Score-Matched Analysis
DOI: https://doi.org/10.2147/COPD.S373595
2022-09-13
International Journal of COPD
Abstract:Thotsaporn Morasert, 1 Orakarn Kriengwattanakul, 2 Prapasri Kulalert 3 1 Pulmonary and Critical Care Medicine, Department of Internal Medicine, Suratthani Hospital, Surat Thani, 84000, Thailand; 2 Department of Internal Medicine, Suratthani Hospital, Surat Thani, 84000, Thailand; 3 Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand Correspondence: Thotsaporn Morasert, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Suratthani Hospital, Surat Thani, 84000, Thailand, Tel +66 88 753 2006 ; +66 77 915 600, Email Objective: This study aimed to assess whether the short-term use of macrolide antibiotics during hospitalization can reduce in-hospital all-cause mortality compared to non-macrolide treatment in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A propensity score (PS) matching analysis was performed using retrospective data from the admission records of AECOPD patients in the medical general ward and medical intensive care unit of a tertiary care center between October 2015 and September 2018. The multivariable Cox proportional hazard model was performed to eliminate residual confounding after the PS analysis. Results: The mortality rate was 11.1% of 1528 admissions in the PS matching cohort. Approximately 70% of patients had respiratory failure requiring intubation on initial admission, and 34% had pneumonia. Macrolide treatment significantly reduced in-hospital mortality among AECOPD patients (adjusted hazard ratio, 0.55; 95% confidence interval 0.32– 0.96; P =0.034). Clarithromycin was the most commonly prescribed macrolide (80%). Conclusion: Macrolide antibiotics reduced in-hospital mortality in hospitalized AECOPD patients. The combination of antimicrobial and immunomodulatory effects of macrolide treatment could play an essential role. Keywords: macrolides, AECOPD, mortality, propensity score-matched An acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is defined as an acute worsening of respiratory symptoms that may cause a progressive decline in lung function. 1 The infectious agent in exacerbation can be viral or bacterial. 2 The international guidelines 3,4 recommend considering empiric antibiotic therapy for AECOPD patients who are most likely to have a bacterial infection and for the most ill patients who require hospitalization. 5–7 In addition, many randomized controlled trials (RCTs) and cohort studies demonstrated that prompt, appropriate antibiotic treatment could improve clinical outcomes that reduced in-hospital mortality, 8,9 all-cause mortality, 10 and the composite outcome of treatment failure 11 in selected patients with AECOPD. However, the initial choice of empiric antibiotic therapy is not standardized and should be guided by prior antibiotic use, AECOPD severity, local bacterial resistance, and the likelihood that Pseudomonas species are present. 3 The commonly used initial empirical antibiotics are aminopenicillin with clavulanic acid and macrolides. 3 However, in patients with frequent exacerbations, severe airflow limitation, 12 or mechanical ventilation is required, 6 a culture from sputum or tracheal suction should be performed to detect resistant organisms, especially gram-negative bacteria. Macrolides are antibiotics that are effective against gram-positive and some gram-negative bacteria. They are also active against atypical bacteria such as Mycoplasma pneumoniae and Chlamydophila pneumoniae . Although a viral infection can be involved in AECOPD, there is no significant evidence that macrolides might have a direct benefit in viral infections. However, a recent extensive literature review proposed that macrolides may improve the clinical course of viral respiratory infections through anti-inflammatory and immunomodulatory effects. 13 The immunomodulatory effect of long-term use of macrolide antibiotics can decrease the rate of AECOPD recurrence. 14 Long-term use of macrolides was reported in a meta-analysis to significantly reduce exacerbations due to immunomodulatory properties. The latest GOLD 2021 recommends using macrolide antibiotics in patients who continue to have exacerbations while optimizing inhaled therapy. 3 A published RCT compared azithromycin to placebo taken daily for one year. Azithromycin was shown to decrease the frequency of exacerbations and improve the quality of life, 15 especially in those who were not current smokers. 16 However, the benefit of macrolides in the short-term m -Abstract Truncated-
respiratory system